Hoffman RM - Search Results

1

Exploiting methionine restriction for cancer treatment.

Chaturvedi S, Hoffman RM, Bertino JR. Chaturvedi S, et al. Among authors: hoffman rm. Biochem Pharmacol. 2018 Aug;154:170-173. doi: 10.1016/j.bcp.2018.05.003. Epub 2018 May 4. Biochem Pharmacol. 2018. PMID: 29733806 Review.

2

Bax-induction gene therapy of pancreatic cancer.

Pirocanac EC, Nassirpour R, Yang M, Wang J, Nardin SR, Gu J, Fang B, Moossa AR, Hoffman RM, Bouvet M. Pirocanac EC, et al. Among authors: hoffman rm. J Surg Res. 2002 Aug;106(2):346-51. doi: 10.1006/jsre.2002.6473. J Surg Res. 2002. PMID: 12175991

3

Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.

Sun FX, Tohgo A, Bouvet M, Yagi S, Nassirpour R, Moossa AR, Hoffman RM. Sun FX, et al. Among authors: hoffman rm. Cancer Res. 2003 Jan 1;63(1):80-5. Cancer Res. 2003. PMID: 12517781

4

PEG-methioninase.

Hoffman RM. Hoffman RM. Adv Exp Med Biol. 2003;519:69-79. doi: 10.1007/0-306-47932-X_5. Adv Exp Med Biol. 2003. PMID: 12675209 Review. No abstract available.

5

Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter.

Katz MH, Spivack DE, Takimoto S, Fang B, Burton DW, Moossa AR, Hoffman RM, Bouvet M. Katz MH, et al. Among authors: hoffman rm. Ann Surg Oncol. 2003 Aug;10(7):762-72. doi: 10.1245/aso.2003.01.021. Ann Surg Oncol. 2003. PMID: 12900367

6

A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.

Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. Katz MH, et al. Among authors: hoffman rm. J Surg Res. 2003 Jul;113(1):151-60. doi: 10.1016/s0022-4804(03)00234-8. J Surg Res. 2003. PMID: 12943825

7

Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates.

Yang Z, Wang J, Yoshioka T, Li B, Lu Q, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM. Yang Z, et al. Among authors: hoffman rm. Clin Cancer Res. 2004 Mar 15;10(6):2131-8. doi: 10.1158/1078-0432.ccr-03-0068. Clin Cancer Res. 2004. PMID: 15041734

8

An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer.

Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. Katz MH, et al. Among authors: hoffman rm. Clin Exp Metastasis. 2004;21(1):7-12. doi: 10.1023/b:clin.0000017160.93812.3b. Clin Exp Metastasis. 2004. PMID: 15065597

9

Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.

Yang Z, Sun X, Li S, Tan Y, Wang X, Zhang N, Yagi S, Takakura T, Kobayashi Y, Takimoto A, Yoshioka T, Suginaka A, Frenkel EP, Hoffman RM. Yang Z, et al. Among authors: hoffman rm. Cancer Res. 2004 Aug 15;64(16):5775-8. doi: 10.1158/0008-5472.CAN-04-1406. Cancer Res. 2004. PMID: 15313919

10

PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.

Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP, Hoffman RM. Yang Z, et al. Among authors: hoffman rm. Cancer Res. 2004 Sep 15;64(18):6673-8. doi: 10.1158/0008-5472.CAN-04-1822. Cancer Res. 2004. PMID: 15374983

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results